Gary M. Winer
Gary M. Winer's purchase track record
How the stock did after each of Gary M. Winer's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/16/2025 | HCWB | $10K | -54.3% | -66.5% | +13.0% |
| 5/8/2025 | HCWB | $60K | -36.9% | -53.6% | +18.6% |
| 8/28/2024 | LNSR | $8K | +64.7% | +102.8% | +6.5% |
| 8/20/2024 | LNSR | $10K | +84.0% | +152.2% | +9.5% |
| 8/12/2024 | LNSR | $6K | +74.5% | +160.3% | +13.5% |
| 11/22/2023 | LNSR | $630 | +100.8% | +77.6% | +16.5% |
| 11/10/2023 | LNSR | $5K | +111.9% | +66.5% | +18.3% |
| 9/13/2023 | HCWB | $3K | -38.6% | -26.7% | +15.6% |
| 9/5/2023 | HCWB | $2K | -41.5% | -19.5% | +12.9% |
| 8/10/2023 | LNSR | $6K | -38.8% | +29.0% | +11.8% |
| 5/30/2023 | HCWB | $2K | +27.5% | -21.5% | +8.3% |
| 11/16/2022 | LNSR | $19K | -24.6% | -43.8% | +5.1% |
| 8/17/2022 | LNSR | $30K | -30.1% | -47.3% | -3.0% |
| 6/6/2022 | HCWB | $12K | +21.4% | -3.7% | -3.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
HCW Biologics Included in After-Market Movers List. HCW Biologics was listed among healthcare stocks moving in Friday's after-market session. The stock is currently trading near its 52-week low, with technical indicators showing oversold conditions. This inclusion highlights recent price volatility, though no specific catalyst for the move was detailed in the provided news.
Transaction History
| LNSR | ▲ Buy | Grant | 17,421 | $0 | 6/3/2026 | View on chart |
| LNSR | ▲ Buy | Grant | 7,374 | $0 | 5/23/2025 | View on chart |
| HCWB | ▲ Buy | Open Market | 1,342 | $10K | 5/16/2025 | View on chart |
| HCWB | ▲ Buy | Open Market | 2,308 | $60K | 5/8/2025 | View on chart |
| LNSR | ▲ Buy | Open Market | 685 | $3K | 9/3/2024 | View on chart |
| LNSR | ▲ Buy | Open Market | 1,000 | $4K | 8/28/2024 | View on chart |
| LNSR | ▲ Buy | Open Market | 500 | $2K | 8/27/2024 | View on chart |
| LNSR | ▲ Buy | Open Market | 802 | $4K | 8/26/2024 | View on chart |
| LNSR | ▲ Buy | Open Market | 2 | $9 | 8/22/2024 | View on chart |
| LNSR | ▲ Buy | Open Market | 500 | $2K | 8/21/2024 | View on chart |
| LNSR | ▲ Buy | Open Market | 500 | $2K | 8/20/2024 | View on chart |
| LNSR | ▲ Buy | Open Market | 6 | $24 | 8/16/2024 | View on chart |
| LNSR | ▲ Buy | Open Market | 1,000 | $4K | 8/14/2024 | View on chart |
| LNSR | ▲ Buy | Open Market | 500 | $2K | 8/12/2024 | View on chart |
| LNSR | ▲ Buy | Grant | 22,000 | $0 | 5/7/2024 | View on chart |
| LNSR | ▲ Buy | Open Market | 300 | $630 | 11/22/2023 | View on chart |
| LNSR | ▲ Buy | Open Market | 1,000 | $2K | 11/16/2023 | View on chart |
| LNSR | ▲ Buy | Open Market | 500 | $1K | 11/15/2023 | View on chart |
| LNSR | ▲ Buy | Open Market | 1,000 | $2K | 11/10/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 162 | $337 | 9/14/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 879 | $2K | 9/14/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 500 | $1K | 9/13/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 46 | $92 | 9/13/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 500 | $1K | 9/12/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 99 | $203 | 9/11/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 1 | $2 | 9/8/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 63 | $123 | 9/7/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 400 | $700 | 9/5/2023 | View on chart |
| LNSR | ▲ Buy | Open Market | 705 | $3K | 8/11/2023 | View on chart |
| LNSR | ▲ Buy | Open Market | 1,000 | $4K | 8/10/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 500 | $750 | 5/31/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 850 | $1K | 5/30/2023 | View on chart |
| LNSR | ▲ Buy | Grant | 9,288 | $0 | 5/25/2023 | View on chart |
| LNSR | ▲ Buy | Open Market | 976 | $4K | 11/23/2022 | View on chart |
| LNSR | ▲ Buy | Open Market | 1,524 | $5K | 11/22/2022 | View on chart |
| LNSR | ▲ Buy | Open Market | 1,500 | $6K | 11/17/2022 | View on chart |
| LNSR | ▲ Buy | Open Market | 1,000 | $4K | 11/16/2022 | View on chart |
| LNSR | ▲ Buy | Open Market | 2,000 | $12K | 8/18/2022 | View on chart |
| LNSR | ▲ Buy | Open Market | 1,000 | $6K | 8/17/2022 | View on chart |
| LNSR | ▲ Buy | Open Market | 2,000 | $12K | 8/17/2022 | View on chart |
| HCWB | ▲ Buy | Open Market | 1,500 | $3K | 6/10/2022 | View on chart |
| HCWB | ▲ Buy | Open Market | 1,000 | $2K | 6/9/2022 | View on chart |
| HCWB | ▲ Buy | Open Market | 1,000 | $2K | 6/8/2022 | View on chart |
| HCWB | ▲ Buy | Open Market | 1,000 | $2K | 6/7/2022 | View on chart |
| HCWB | ▲ Buy | Open Market | 1,000 | $2K | 6/6/2022 | View on chart |
| LNSR | ▲ Buy | Grant | 4,285 | $0 | 5/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Lucid Capital Markets Begins Coverage of LENSAR, Sets $11 Target
Lucid Capital Markets has started coverage on LENSAR and issued a positive rating. The firm set a price target of $11, which sits near the upper end of the company’s 52‑week range. The new outlook may attract attention from investors looking at LENSAR’s valuation relative to its peers. The coverage adds a fresh perspective to the market’s view of the stock.
Lucid Capital Markets Begins Coverage of LENSAR, Sets $11 Target. Lucid Capital Markets has started coverage on LENSAR and issued a positive rating. The firm set a price target of $11, which sits near the upper end of the company’s 52‑week range. The new outlook may attract attention from investors looking at LENSAR’s valuation relative to its peers. The coverage adds a fresh perspective to the market’s view of the stock.